EXELIXIS, INC. (EXEL) Form 10-Q — Oct 29, 2026
Exelixis reported strong Q3 2026 results with total revenues of $658.7M, up 10% year-over-year, driven by CABOMETYX net product revenues of $603.2M (+12%). Net income rose to $218.1M, or $0.85 per diluted share, versus $193.6M ($0.69) in Q3 2025. The company won a key patent appeal against MSN in August 2026, blocking generic CABOMETYX entry before January 15, 2030, and settled with Azurity in October 2026 with a generic license effective December 1, 2030. However, the FDA extended the PDUFA review date for zanzalintinib in metastatic colorectal cancer by three months to March 3, 2027.
Key figures
- Eps
- $0.88 basic / $0.85 diluted
- Revenue
- 658696000
- Net Income
- 218095000
- Revenue Yoy
- 10%
- Total Assets
- 2513489000
- Shares Outstanding
- 244010895
- Srp remaining
- $347.9M
- Buyback avg price
- $54.03 per share
- Cabometyx q3 revenue
- $603.2M (+12% YoY)
- Nine month net income
- $640.6M
- Diluted eps nine month
- $2.46
- May 2026 srp repurchased
- $402.1M
- Zanzalintinib pdufa date
- March 3, 2027 (extended from December 3, 2026)
- Marketable securities total
- $1,095,003K
- Net product revenues q3 2026
- $604.9M vs $542.9M prior year (+11%)
- Operating cash flow nine month
- $839.5M
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.